Key Documents
Jonathan S. Berek
- Professor, Obstetrics & Gynecology
Contact Information
- Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr Clinic C Gynecologic Oncology Clinic Stanford, CA 94305 Telephone Work (650) 498-6000 Fax
- Academic Offices
Personal Information Email jberek@stanford.edu Tel (650) 723-5533Administrative Contact Kerry Garcia Assistant to the Chair Email kerryg@stanford.edu Tel Work 650-723-5533Not for medical emergencies or patient use
Clinical Focus
- Cancer > Gynecologic Cancer
- Gynecologic Oncology
- Gynecologic Cancers - Gynecologic Oncology
- Ovarian Cancer
- Uterine Cancer
- Uterine Cervical Cancer
- Vaginal Cancer
- Vulvar Cancer
- Trophoblastic Neoplasms
- Pelvic Reconstructive Surgery
- Neovagina
Administrative Appointments
- Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine , (2005– present )
- Director, Women's Cancer Program, Stanford Cancer Center , (2008– present )
Professional Education
- Board Certification: Gynecologic Oncology, American Board of Obstetrics and Gynecology (1983)
- UCLA - School of Medicine (1981) CA
- Harvard Medical School, Brigham & Women's Hospital (1979) MA
- Harvard Medical School, Brigham & Women's Hospital (1976) MA
- Board Certification: Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (1982)
- Johns Hopkins University School of Medicine (1975) MD
Postdoctoral Advisees
Community & International Work
- President, International Gynecologic Cancer Society, International More »
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.
- Consulting: Telik, Inc.
Clinical Trials
- A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS) Recruiting
- Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer Recruiting
- Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Recruiting
- Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Recruiting
- AZD6244 in Treating Woman With Recurrent Low-Grade Ovarian Cancer Recruiting
- Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Recruiting
- Second Curettage in Treating Patients With Persistent Non-Metastatic Gestational Trophoblastic Tumor Recruiting
- Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries Recruiting
- Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA) No longer recruiting
- Safety and Efficacy Study of the Trifunctional Antibody Catumaxomab to Treat Ovarian Cancer in Women After a Complete Response to Chemotherapy Completed
- Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer No longer recruiting
- Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer No longer recruiting
- Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer No longer recruiting
- Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Suspended
Publications
- J Clin Oncol. 2009; (3): 418-25
- Obstet Gynecol. 2009; (5): 1027-37
- Int J Gynecol Cancer. 2009; (2): 223-9
- J Immunother. 2008 Feb-Mar; (2): 207-14
- Am J Obstet Gynecol. 2008; (2): 216.e1-5
- Gynecol Oncol. 2008; (3): 652-7
- Gynecol Oncol. 2008; (3): 568-71
- Am J Obstet Gynecol. 2008; (2): 218.e1-6
- Menopause. 2007 May-Jun; (3 Pt 2): 580-5
- Curr Opin Obstet Gynecol. 2007; (4): 350-4
- Obstet Gynecol. 2007; (1): 12-9
- Obstet Gynecol. 2007; (6): 1342-50
- Obstet Gynecol. 2007; (2 Pt 1): 296-301
- Br J Cancer. 2007; (12): 1817-22
- Gynecol Oncol. 2007; (3): 505-7
- J Clin Oncol. 2007; (20): 2975-82
- Gynecol Oncol. 2007; (2): 396-400
- Clin Obstet Gynecol. 2007; (2): 354-61
- Obstet Gynecol. 2007; (3): 655-62
- Cancer. 2007; (12): 2454-60
- Int J Gynecol Cancer. 2006 Mar-Apr; (2): 463-9
- Int J Gynecol Cancer. 2006 Jan-Feb; (1): 125-34
- Lancet. 2006; (9522): 1558-60
- Gynecol Oncol. 2006; (3): 1095-9
- Br J Cancer. 2006; (10): 1314-20
- Curr Opin Oncol. 2006; (5): 507-15
- Obstet Gynecol. 2006; (3 Pt 1): 521-8
- Cancer Res. 2006; (6): 2904-6
- Climacteric. 2006; (5): 396-8; author reply 398-400
- Gynecol Oncol. 2005; (2): 685-92
- Gynecol Oncol. 2005; (1): 108-11
- Gynecol Oncol. 2005; (3): 721-8
- Gynecol Oncol. 2005; (1): 153-9
- Expert Rev Anticancer Ther. 2005; (1): 87-96
- J Cancer Educ. 2005; (3): 143-9
- Acad Med. 2004; (7): 711-6
- J Clin Oncol. 2004; (17): 3507-16
- Expert Opin Biol Ther. 2004; (7): 1159-65
- Clin Cancer Res. 2004; (8): 2681-6
- Cancer J. 2003 Sep-Oct; (5): 325-6
- Int J Gynecol Cancer. 2003 May-Jun; (3): 368-70
- Int J Gynecol Cancer. 2003 Mar-Apr; (2): 138-41
- Int J Gynecol Cancer. 2003 Mar-Apr; (2): 120-4
- Gynecol Oncol. 2003; (1 Pt 2): S105-9; discussion S110-3
- Gynecol Oncol. 2003; (1): 177-80
- Obstet Gynecol. 2003; (3): 612-9
- Eur J Cancer. 2003; (13): 1818-27
- Gynecol Oncol. 2003; (2): 325-30
- Am J Obstet Gynecol. 2003; (3 Suppl): S2-5; discussion S6-7
- J Clin Oncol. 2003; (10 Suppl): 129s-132s
- J Clin Oncol. 2003; (10 Suppl): 168s-174s
- Int J Gynecol Cancer. 2002 Sep-Oct; (5): 454-8
- J Reprod Med. 2001; (7): 621-9; discussion 629-30
- Semin Surg Oncol. 2000 Jul-Aug; (1): 3-10
- Gynecol Obstet Fertil. 2000 Jul-Aug; (7-8): 576-83
- Care Manag J. 2000; (1): 44-53
- Lancet. 2000; (9223): 6-7
- J Am Coll Surg. 2000; (2): 212-5
- J Clin Oncol. 2000; (8): 1606-13
- Gynecol Oncol. 2000; (2): 225-6
- Oncology (Williston Park). 1999; (12): 1665-70; discussion 1675-8, 1681-2
- J Immunol. 1999; (12): 6378-85
- Obstet Gynecol. 1999; (5 Pt 2): 856
- Gynecol Oncol. 1999; (1): 48-52
- Ann Oncol. 1999; 87-92
- Ann Oncol. 1999; 69-73
- Ann Oncol. 1999; 3-7
- Gynecol Oncol. 1999; (1): 10-4
- Gynecol Oncol. 1998; (2): 204-10
- Gynecol Oncol. 1998; (3): 410-5
- Obstet Gynecol. 1998; (4 Pt 2): 659-61
- Cancer Treat Res. 1998; 253-76
- Med Care. 1998; (3): 397-410
- Curr Opin Obstet Gynecol. 1998; (1): 51-5
- Int J Gynecol Cancer. 1997; (1): 1-13
- Cancer J Sci Am. 1996 May-Jun; (3): 132-3
- Gynecol Oncol. 1996; (1): 97-100
- Am J Obstet Gynecol. 1996; (4): 1102-6; discussion 1106-8
- Eur J Obstet Gynecol Reprod Biol. 1996; (2): 249-53
- Gynecol Oncol. 1996; (3): 352-7
- Cancer. 1995; (10 Suppl): 2092-6
- Lancet. 1995; (8969): 200
- Int J Radiat Oncol Biol Phys. 1995; (5): 1543-4
- Int J Gynecol Cancer. 1995; (6): 449-458
- Gynecol Oncol. 1995; (2): 164-8
- N Engl J Med. 1995; (10): 675-7
- J Clin Oncol. 1995; (7): 1589-99
- Semin Surg Oncol. 1994 Jul-Aug; (4): 268-75
- Cancer Treat Res. 1994; 1-13
- Obstet Gynecol Clin North Am. 1994; (1): 79-92
- Obstet Gynecol. 1994; (3): 414-8
- J Reprod Med. 1994; (4): 241-8
- Am J Obstet Gynecol. 1994; (4): 1121-8; discussion 1128-30
- Am J Obstet Gynecol. 1994; (4): 974-9; discussion 979-80
- Gynecol Oncol. 1994; (1): 55-8
- Gynecol Oncol. 1994; (2): 142-6
- J Am Assoc Gynecol Laparosc. 1994; (4, Part 2): S27
- Curr Opin Oncol. 1994; (5): 513-8
- Gynecol Oncol. 1994; (1): 108-10
- Obstet Gynecol. 1994; (4 Pt 2): 724-6
- Obstet Gynecol. 1994; (5): 897
- J Am Coll Surg. 1994; (6): 733-7
- Int J Gynecol Cancer. 1994; (1): 43-51
- Exp Cell Res. 1993; (2): 332-9
- Am J Obstet Gynecol. 1993; (6 Pt 2): 1980-5
- Gynecol Oncol. 1993; (3): 279-83
- Gynecol Oncol. 1993; (1): 8-15
- Gynecol Oncol. 1993; (3): 389-93
- Ann Oncol. 1993; 71-7
- Clin Geriatr Med. 1993; (1): 131-43
- Gynecol Oncol. 1993; (2): 214-20
- Ann Oncol. 1993; 3-16
- Ann Oncol. 1993; 83-8
- Gynecol Oncol. 1993; (3): 338-41
- Med Care. 1992; (3): 216-30
- Curr Opin Obstet Gynecol. 1992; (1): 109-19
- Gynecol Oncol. 1992; (1): 1-2
- Eur J Cancer. 1992; (4-5): 719-21
- Cytokine. 1992; (5): 385-90
- Gynecol Oncol. 1992; (1): 3-8
- Am J Obstet Gynecol. 1992; (3): 997-1007
- Hematol Oncol Clin North Am. 1992; (4): 941-65
- In Vivo. 1991 Nov-Dec; (6): 583-8
- Am J Obstet Gynecol. 1991; (4): 997-1003; discussion 1003-4
- Gynecol Oncol. 1991; (1): 70-3
- Gynecol Oncol. 1991; (3): 237-43
- Gynecol Oncol. 1991; (3): 197-201
- Am Surg. 1991; (5): 327-9
- Am J Obstet Gynecol. 1991; (4): 1038-42; discussion 1042-3
- Anticancer Res. 1990 Mar-Apr; (2A): 441-6
- Clin Obstet Gynecol. 1990; (4): 852-62
- Cancer Chemother Pharmacol. 1990; (1): 1-8
- Cancer Res. 1990; (21): 6959-65
- Am J Obstet Gynecol. 1990; (5 Pt 1): 1574-7
- Obstet Gynecol. 1990; (4): 623-6
- J Clin Oncol. 1990; (10): 1610-2
- Gynecol Oncol. 1990; (3): 333-9
- Gynecol Oncol. 1990; (3): 309-14
- West J Med. 1990; (1): 50-61
- Gynecol Oncol. 1990; (3): 311-4
- Obstet Gynecol. 1990; (6): 1023-8
- Invest New Drugs. 1990; (2): 191-4
- N Engl J Med. 1990; (15): 1076-8
- Gynecol Oncol. 1990; (1): 9-16
- Gynecol Oncol. 1990; (3): 380-2
- Cancer Res. 1990; (22): 7364-70
- Obstet Gynecol. 1989; (4): 663-6
- Cancer. 1989; (2): 434-41
- Gynecol Oncol. 1989; (1): 66-9
- Gynecol Oncol. 1989; (3): 335-9
- Curr Opin Oncol. 1989; (1): 75-81
- Obstet Gynecol. 1989; (5 Pt 1): 793-7
- Gynecol Oncol. 1989; (1): 54-60
- Blood. 1989; (2): 805-9
- Gynecol Oncol. 1989; (3): 338-40
- J Clin Oncol. 1989; (4): 457-65
- Curr Probl Cancer. 1988 Mar-Apr; (2): 61-131
- Am J Obstet Gynecol. 1988; (2): 341-6
- Cancer Res. 1988; (20): 5853-9
- Obstet Gynecol. 1988; (2): 261-9
- Obstet Gynecol. 1988; (5): 782-8
- Cancer Immunol Immunother. 1988; (3): 246-54
- Recent Results Cancer Res. 1988; 47-56
- Nat Immun Cell Growth Regul. 1988; (4): 216-25
- Cancer. 1987; (7): 1561-6
- Obstet Gynecol. 1987; (5): 759-64
- Appl Pathol. 1987; (1): 47-56
- Cancer. 1987; (7): 1552-60
- Anal Quant Cytol Histol. 1987; (1): 17-24
- Obstet Gynecol. 1987; (2): 223-7
- Obstet Gynecol. 1986; (6): 783-8
- Am J Obstet Gynecol. 1986; (1): 56-60
- Cancer Immunol Immunother. 1986; (1): 24-30
- Obstet Gynecol. 1986; (2): 241-4
- Gynecol Oncol. 1986; (1): 101-4
- Obstet Gynecol. 1986; (4): 478-82
- Obstet Gynecol. 1986; (5): 685-9
- Obstet Gynecol. 1985; (1): 60-6
- J Natl Cancer Inst. 1985; (2): 349-55
- Am J Obstet Gynecol. 1985; (8): 1003-10
- Cancer Res. 1985; (9): 4215-8
- Cancer Treat Rev. 1985; 23-32
- Obstet Gynecol. 1985; (1): 46-52
- Cancer Res. 1985; (9): 4447-53
- Cancer Res. 1984; (5): 1871-5
- J Biol Response Mod. 1984; (4): 371-8
- Obstet Gynecol. 1984; (2): 155-62
- Obstet Gynecol. 1984; (3): 318-23
- Cancer. 1984; (10): 2056-61
- Obstet Gynecol. 1984; (2): 207-12
- Obstet Gynecol. 1984; (5): 715-20
- Cancer Res. 1984; (11): 5118-23
- Obstet Gynecol. 1984; (5): 708-14
- J Immunol. 1984; (1): 519-26
- Obstet Gynecol. 1983; (1): 134-5
- Obstet Gynecol. 1983; (6): 743-8
- Clin Obstet Gynaecol. 1983; (2): 213-22
- Gynecol Oncol. 1983; (3): 299-304
- Cancer Treat Rep. 1983; (12): 1085-92